Stephens Kristin 4
4 · Syros Pharmaceuticals, Inc. · Filed Nov 2, 2023
Insider Transaction Report
Form 4
Stephens Kristin
Chief Development Officer
Transactions
- Exercise/Conversion
Common Stock
2023-10-31+17,000→ 21,465 total - Exercise/Conversion
Restricted Stock Units
2023-10-31−17,000→ 17,000 total→ Common Stock (17,000 underlying) - Tax Payment
Common Stock
2023-11-01$2.22/sh−5,676$12,601→ 15,789 total
Footnotes (4)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
- [F2]Represents shares used to cover tax withholding on a restricted stock unit release.
- [F3]Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F4]Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and are scheduled to vest as to one half (50%) of the shares on October 31, 2024.